Skip to main content

CRBP

Stock
Health Care
Biotechnology

Performance overview

CRBP Price
Price Chart

Forward-looking statistics

Beta
1.75
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company'sĀ development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Company info

SectorHealth Care
IndustryBiotechnology
Employees35
Market cap$471.6M

Fundamentals

Enterprise value-$45.5M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity2.25

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$4.24
Dividend per share—
Revenue per share$0.00
Avg trading volume (30 day)$2M
Avg trading volume (10 day)$3M
Put-call ratio—

Macro factor sensitivity

Growth+4.7
Credit+3.9
Liquidity+0.5
Inflation-2.8
Commodities-0.6
Interest Rates-3.4

Valuation

Dividend yield0.00%
PEG Ratio-1.47
Price to sales—
P/E Ratio-1.47
Enterprise Value to Revenue—
Price to book0.74

Upcoming events

Next earnings dayMay 6, 2025
Next dividend day—
Ex. dividend day—

News

3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.

Zacks Investment Research (May 23, 2025)
Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Corbus Pharmaceuticals Holdings, Inc. CRBP received reaffirmed buy ratings from both H.C. Wainwright and Oppenheimer this week, with analysts citing the company's diversified pipeline as a key driver for future growth, despite a sharp stock decline after Novo Nordisk's NVO mid-stage data on its obesity drug.

Benzinga (September 23, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free